Excelra announced a partnership with Patcore, Inc., providing greater access to Excelra’s scientific data and analytics products for customers in Japan.
Excelra is one of the leading global data and digital insights organization. Its GOSTAR platform is the largest manually curated medicinal chemistry intelligence database, providing comprehensive, structured SAR data for more than 9 million compounds. Excelra’s GOBIOM contains the most extensive manually curated collection of validated and putative biomarkers, providing critical insights into the relationship between biomarker and disease.
Patcore is a highly specialized informatics organization, supporting researchers in life sciences companies and chemical industries. The partnership supports Excelra’s growth in Japan, leveraging Patcore’s experience working with some of Japan’s largest pharmas, biotechs, chemical companies, and government institutions.
Recommended AI News: New Slack Innovations and Salesforce Customer 360 Integrations Unlock Team Productivity, Adding Value to the Digital HQ
“When it comes to bio-medical data, Excelra’s GOSTAR and other data products are the leading solutions available today for global drug discovery and translational researchers. Japan has been a strategic focus for Excelra, and the demand for the most accurate and up-to-date data set is growing rapidly. Patcore is giving us the opportunity to expand our presence, and I am confident that by harnessing the synergies of Patcore and Excelra, Japanese life science organizations will be able to accelerate research and achieve their molecule-to-market objectives faster,” said Gabriele Staples, Global Commercial & Marketing Head, Excelra.
“The partnership with Excelra’s scientific products and our existing offerings will drive data enrichment, competitive intelligence, and power prediction engines with AI/ML initiatives for our customers,” said Fumiaki Aruga, COO, Patcore, Inc.
Recommended AI News: Wiha Tools USA Adopts New Salsify Connector to Amazon A+ API
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.